Fabris P - Search Results

1

Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.

Santantonio T, Fasano M, Sagnelli E, Tundo P, Babudieri S, Fabris P, Toti M, Di Perri G, Marino N, Pizzigallo E, Angarano G; Acute Hepatitis C Study Group. Santantonio T, et al. Among authors: fabris p. Hepatology. 2014 Jun;59(6):2101-9. doi: 10.1002/hep.26991. Epub 2014 Apr 29. Hepatology. 2014. PMID: 24442928 Clinical Trial.

2

Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.

Fabris P, Carlotto A, Del Bianco T, Malfatti F, Tramarin A, Miotti MA, Baldo V, Floreani A, Giordani MT, Grasso A. Fabris P, et al. Eur J Gastroenterol Hepatol. 2013 Dec;25(12):1396-401. doi: 10.1097/MEG.0b013e328362dc22. Eur J Gastroenterol Hepatol. 2013. PMID: 23743559 Clinical Trial.

3

Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.

Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Santantonio T, et al. Among authors: fabris p. Clin Infect Dis. 2006 Nov 1;43(9):1154-9. doi: 10.1086/507640. Epub 2006 Sep 27. Clin Infect Dis. 2006. PMID: 17029134 Free article.

4

Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.

Grasso A, Malfatti F, De Leo P, Martines H, Fabris P, Toscanini F, Anselmo M, Menardo G. Grasso A, et al. Among authors: fabris p. J Hepatol. 2009 Dec;51(6):984-90. doi: 10.1016/j.jhep.2009.07.008. Epub 2009 Jul 23. J Hepatol. 2009. PMID: 19695729 Clinical Trial.

5

Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis.

Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, de Lalla F. Fabris P, et al. J Hepatol. 1998 Mar;28(3):514-7. doi: 10.1016/s0168-8278(98)80328-0. J Hepatol. 1998. PMID: 9551692 Review.

6

Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Cozzolongo R, et al. Among authors: fabris p. Eur J Gastroenterol Hepatol. 2006 Jun;18(6):689-92. doi: 10.1097/00042737-200606000-00018. Eur J Gastroenterol Hepatol. 2006. PMID: 16702861

7

Impact of liver steatosis on virological response in [corrected] Italian patients with chronic hepatitis C treated with peg-interferon alpha-2b plus ribavarin.

Fabris P, Floreani A, Carlotto A, Baldo V, Bozzola L, Giordani MT, Negro F, Rassu M, Tramarin A, de Lalla F. Fabris P, et al. Aliment Pharmacol Ther. 2005 May 1;21(9):1173-8. doi: 10.1111/j.1365-2036.2005.02452.x. Aliment Pharmacol Ther. 2005. PMID: 15854181

8

Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.

Degasperi E, Spinetti A, Lombardi A, Landonio S, Rossi MC, Pasulo L, Pozzoni P, Giorgini A, Fabris P, Romano A, Lomonaco L, Puoti M, Vinci M, Gatti F, Carolo G, Zoncada A, Bonfanti P, Russo FP, Aghemo A, Soria A, Centenaro R, Maggiolo F, Rovere P, Pasin F, Paon V, Faggiano G, Vario A, Grossi G, Soffredini R, Carriero C, Paolucci S, Noventa F, Alberti A, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia and Veneto Study Groups. Degasperi E, et al. Among authors: fabris p. J Hepatol. 2019 Dec;71(6):1106-1115. doi: 10.1016/j.jhep.2019.07.020. Epub 2019 Aug 6. J Hepatol. 2019. PMID: 31433303

9

Clinical features of bacterial meningitis in Italy: a multicenter prospective observational study.

Lazzarini L, Toti M, Fabris P, Conti E, Magni G, Mazzotta F, De Lalla F; Mentore Study Group Clinical Investigators. Lazzarini L, et al. Among authors: fabris p. J Chemother. 2008 Aug;20(4):478-87. doi: 10.1179/joc.2008.20.4.478. J Chemother. 2008. PMID: 18676229

10

Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients.

Fabris P, Tositti G, Negro F, Marranconi F, Infantolino D, Rassu M, De Lalla F. Fabris P, et al. Aliment Pharmacol Ther. 1999 Oct;13(10):1329-34. doi: 10.1046/j.1365-2036.1999.00613.x. Aliment Pharmacol Ther. 1999. PMID: 10540048 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

149 results

Search Page

Filters